我们的网站为什么显示成这样?

可能因为您的浏览器不支持样式,您可以更新您的浏览器到最新版本,以获取对此功能的支持,访问下面的网站,获取关于浏览器的信息:

|本期目录/Table of Contents|

基于网络药理学的六味地黄丸治疗冠心病的分子机制研究*(PDF)

《云南中医学院学报》[ISSN:1000-2723/CN:53-1048/R]

期数:
2019年03期
页码:
74-82
栏目:
方药研究
出版日期:
2020-04-20

文章信息/Info

Title:
Molecular Mechanism of Liuwei Dihuang Pills in Treating Coronary Heart Disease Based on Network Pharmacology
文章编号:
1000-2723(2019)03-0074-09
作者:
杨志华1刘 琰1闫海峰1姬艳苏2王淑萍2△
(1. 天津中医药大学,天津 301617;2. 武警特色医学中心,天津 300162)
Author(s):
YANG Zhihua1 LIU Yan1 YAN Haifeng1 JI Yansu2 WANG Shuping2
( 1. Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China; 2. Characteristic Medical Center of PAP, Tianjin 300162, China)
关键词:
六味地黄丸冠心病网络药理学分子机制生物过程信号通路
Keywords:
Liuwei Dihuang Pills coronary heart disease network pharmacology molecular mechanisms biological processes signaling pathway
分类号:
R285.5
DOI:
10.19288/j.cnki.issn.1000-2723.2019.03.013
文献标识码:
A
摘要:
目的运用网络药理学分析六味地黄丸治疗冠心病的分子机制。方法 从中药系统药理学分析平台(TCMSP)获得与六味地黄丸中6味中药相关的所有化学成分和作用靶点,运用 Cytoscape 3.2.1软件构建化合物靶点相互作用网络图,利用TTD、Drugbank、DisGeNET数据库筛选冠心病相关的疾病靶点,将冠心病靶点与药物靶点进行Venn分析,筛选出二者的共同靶点,应用STRING平台构建蛋白-蛋白相互作用(PPI)网络模型。通过DAVID (Version 6.8)数据库对疾病与药物共同靶点进行 Gene Ontology(GO)富集分析、KEGG通路富集分析。结果 共筛选出六味地黄丸的43种主要成分及与治疗冠心病相关的关键靶点85个,靶点主要涉及调节脂多糖代谢、炎症反应、细胞分裂、细胞因子活性、DNA复制及其转录等生物过程,通过参与TNF、HIF-1、PI3K/Akt、Estrogen、TLRs、NF-κB、cGMP-PKG、cAMP等信号通路治疗冠心病。结论 本研究从多角度探索了六味地黄丸治疗冠心病可能的作用机制,揭示了六味地黄丸具有多成分、多靶点和多途径治疗疾病的特点,为其临床应用及进一步研究其药效作用机制奠定基础。
Abstract:
Objective Using network pharmacology to analyze the molecular mechanism of Liuwei Dihuang Pills in treating coronary heart disease. Methods Obtained all chemical constituents and targets related to 6 traditional Chinese medicines in Liuwei Dihuang Pills from the Traditional Chinese Medicine Systems Pharmacology Analysis Platform (TCMSP). Cytoscape 3.2.1 software was used to construct a network map of compound target interactions. TTD, Drugbank, and DisGeNET databases were used to screen coronary heart disease-related disease targets. Venn analysis of coronary heart disease targets and drug targets were performed to screen out the common targets. Protein-protein interaction (PPI) network model was constructed by STRING platform. Gene Ontology (GO) enrichment analysis and KEGG pathway enrichment analysis of common targets of diseases and drugs were conducted by DAVID (Version 6.8) database. Results A total of 43 major components of Liuwei Dihuang Pills and 85 key targets related to the treatment of coronary heart disease were screened. The targets are mainly related to the regulation of lipopolysaccharide metabolism, inflammatory reaction, cell division, cytokine activity, DNA replication and transcription. Treatment coronary heart disease by participating in TNF, HIF-1, PI3K/Akt, Estrogen, TLRs, NF-κB, cGMP-PKG, cAMP and other signaling pathways. Conclusion This study explored the possible mechanism of Liuwei Dihuang Pills in the treatment of coronary heart disease from various perspectives, and revealed that Liuwei Dihuang Pills has the characteristics of multi-component, multi-target and multi-channel treatment of diseases, laying a foundation for its clinical application and further study of its pharmacodynamic mechanism.

参考文献/References

[1] 胡盛寿,高润霖,刘力生,等. 《中国心血管病报告2018》概要[J]. 中国循环杂志,2019,34(3):209-220.
[2] 吴勉华. 中医内科学[M]. 9版. 北京:中国中医药出版社,2012:134-135.
[3] 葛均波,徐永健. 内科学[M]. 北京:人民卫生出版社,2013:227.
[4] 毛静远. 阴虚与冠心病初探[J]. 中医药研究,1998(5):5-6.
[5] 邓中甲. 方剂学[M]. 2版. 北京:中国中医药出版社,2010:164.
[6] 王常普. 加用六味地黄丸加减治疗冠心病心绞痛30例[J]. 广西中医药,2015,38(4):27-28.
[7] 李长月,孙兰军. 孙兰军从肾论治冠心病经验[J]. 河南中医,2011,31(12):1365-1366.
[8] 刘征彦. 冠心病临床治验举隅[J]. 现代医药卫生,2008(8):1216-1217.
[9] 任寿山,云文清. 冠心病从肾论治体会[J]. 内蒙古中医药,2000(S1):25-26.
[10] 周文霞,程肖蕊,张永祥. 网络药理学:认识药物及发现药物的新理念[J]. 中国药理学与毒理学杂志,2012,26(1):4-9.
[11] LIU C X, LIU R, FAN H R, et al. Network pharmacology bridges traditional application and modern development of traditional Chinese medicine[J]. Chin Herb Med,2015,7(1):3-17.
[12] MERING C V,JENSEN L J,SNEL B,et al. STRING:knownand predicted protein-protein associations,integrated andtransferred across organisms[J]. Nucleic Acids Res,2005,33:433-437
[13] BIJLSMA J W, BERENBAUM F, LAFEBER F P. Osteoarthritis:an update with relevance for clinical practice[J]. Lancet,2011,377(9783):2115-2126.
[14] NGUYEN U S, ZHANG Y, ZHU Y, et al. Increasing prevalence of knee pain and symptomatic knee osteoarthritis: survey and cohort data[J]. Annal Inter Med,2011,155(11):725-732.
[15] 国家卫生计生委合理用药专家委员会,中国药师协会. 冠心病合理用药指南(第2版)[J]. 中国医学前沿杂志(电子版),2018,10(06):1-130.
[16] 李乃谦. 熟地黄活性成分药理作用的研究进展[J]. 中国处方药,2017,15(01):14-15.
[17] 梁荣琰. 山药的药理学研究及现代化应用[J]. 世界最新医学信息文摘,2015,15(A3):192-193.
[18] 邢增智,陈旺,曾宇. 泽泻的化学成分与药理作用研究进展[J]. 中医药导报,2017,23(15):75-78.
[19] 王松笛. 凤丹皮降血糖的活性成分研究[D]. 武汉:湖北中医药大学,2012.
[20] LI H, XIE Y H, YANG Q, et al. Cardioprotective effect of paeonol and Danshensu combination on Isoproterenol-Indu ced myocardial injury in rats[J]. Plos One,2012,7(11):e48872.
[21] BAO M H, ZHANG Y W, ZHOU H H. Paeonol suppresses oxidized low-density lipoprotein induced endothelial cell apoptosis via activation of LOX-1/p38MAPK/NF-κB pathway[J]. Journal of ethnopharmacology,2013,146(2):543-551.
[22] 陈巧霞,杨光明,潘扬. 山茱萸功能性成分的提取分离及生物活性研究进展[J]. 江苏中医药,2016,48(1):82-85.
[23] 冯启光. 茯苓有效成分的药理学研究概况探析[J]. 世界最新医学信息文摘,2015,15(24):179-180.
[24] AGNIESZKA M, CHALUBINSKI M, MARLENA B, et al. Putative consequences of exposure to Helicobacter pylori infection in patients with coronary heart disease in terms of humoral immune response and inflammation[J]. Archives of Medical Science,2016,12(1):45-54.
[25] 吴春凤,姜焕好,曾东良,等. 银杏叶对冠心病患者血清IL-6和TNF-α的影响[J]. 广东医学,2010,31(2):235-236.
[26] 李明强,刘爱姣. 参麦注射液对冠心病心绞痛患者血清TNF-α和IL-6的影响[J]. 中国实用医药,2011,6(17):142-143.
[27] 张瑞,曹庆伟,李爱平,等. 基于网络药理学的黄芪抗疲劳作用机制研究[J]. 中草药,2019,50(8):1880-1889.
[28] 赵爱华. 冠心病患者血清HIF-1α及HO-1水平的变化及其意义[J]. 当代医学,2011,17(9):48.
[29] 潘晔,殷佳,蔡雪朦,等. 基于PI3K/Akt信号通路探讨中医药治疗冠心病的研究进展[J]. 中草药,2017,48(19):4100-4104.
[30] 胡艳艳. PI3K/Akt/GSK-3β和线粒休ATP敏感钾通道介导原花青素对心肌缺血再灌注损伤的保护作用[D]. 济南:山东大学,2013.
[31] 韩军,宣佳利,胡浩然,等. 金丝桃苷预处理减轻大鼠心肌缺血再灌注损伤作用与PI3K/Akt信号通路的关系[J]. 中国中药杂志,2015,40(1):118-123.
[32] 刘金龙,张永和. 中药对冠心病的治疗作用及其机制探究[J]. 长春中医药大学学报,2019,35(3):589-592.
[33] 赵元,郑红霞,徐颖,等. 中药植物雌激素的研究进展[J]. 中国中药杂志,2017,42(18):3474-3487.
[34] 李自青,闫玉清,张年萍,等. Toll样受体信号通路与冠心病关系的生物信息学分析[J]. 中国全科医学,2019,22(17):2069-2074.
[35] 于泽胜,李沛纯,姚璐,等. 基于NF-κB信号转导通路的中医药干预冠心病研究进展[J]. 中草药,2016,47(9):1614-1618.
[36] 曹选超,黄改荣,王丽霞,等. 冠心病患者外周血NF-κB表达与冠脉危险积分的关系及意义[J]. 中国卫生检验杂志,2011,21(9):2202-2203.
[37] FEIL R, LOHMANN S M, JONGE H, et al. Cyclic GMP-dependent protein kinases and the cardiovascular system:insights from genetically modified mice[J]. Circulation Research,2003,93(10):907-916.
[38] Hofmann F. The biology of cyclic GMP-dependent protein kinases[J]. Journal of Biological Chemistry,2005, 280(1):1-4.
[39] 陈其敬,张云波. 环磷酸腺苷、儿茶酚胺类物质水平在判断冠心病病情和预后方面意义[J]. 中国循证心血管医学杂志,2016,8(9):1059-1061.

备注/Memo

备注/Memo:
收稿日期: 2019 - 04- 03
* 基金项目: 国家自然科学基金青年科学基金项目(81903839)
第一作者简介: 杨志华(1989-),男,在读硕士研究生,研究方向:从事中医内科心血管研究。
△通信作者: 王淑萍,E-mail:wangshuping10 @163.com
更新日期/Last Update: 2020-05-06